Patents for A61P 35 - Antineoplastic agents (221,099)
09/2008
09/04/2008WO2008106168A1 Combination of imidazo [1,5-a] pyrazinyl derivatives with an agent that inhibits serine phosphorylation of irs1 for use in the treatment of cancer
09/04/2008WO2008106131A2 Combination therapy for treatment of immune disorders
09/04/2008WO2008106129A2 Polymeric micelles for combination drug delivery
09/04/2008WO2008105978A1 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization
09/04/2008WO2008105560A1 Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
09/04/2008WO2008105526A1 Macrocyclic compound
09/04/2008WO2008105473A1 Anti-malignant-tumor agent
09/04/2008WO2008105462A1 Method for activation of helper t cell and composition for use in the method
09/04/2008WO2008105408A1 Novel pyrrole derivative having ureide group and aminocarbonyl group as substituents
09/04/2008WO2008105386A1 Rexinoid compound having alkoxy group
09/04/2008WO2008104976A1 Amphipathic carboxylates for the treatment of immune-related disorders
09/04/2008WO2008104812A2 C21-de0xy ansamycin derivatives as antitumor agents
09/04/2008WO2008104754A1 Novel pyrimidine derivatives 698
09/04/2008WO2008104595A1 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
09/04/2008WO2008104524A1 Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
09/04/2008WO2008104387A1 Use of inhibitors of the degradation of p27, in particular argyrin and derivatives thereof, for the treatment of proliferative diseases
09/04/2008WO2008104161A1 ß-CARBOLINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
09/04/2008WO2008104124A1 Screening method of combination pharmaceuticals, pharmaceuticals obtained by the method and uses thereof
09/04/2008WO2008104077A1 Small molecule inhibitors of protein arginine methyltransferases (prmts)
09/04/2008WO2008086462A3 AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
09/04/2008WO2008079814A3 Mapk/erk kinase inhibitors
09/04/2008WO2008077772A3 Combination of a retinoid and a platinum anticancer agent
09/04/2008WO2008058225A3 Methods and compositions for treating cancer using bcl-2 antisense oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents
09/04/2008WO2008057503A3 Compositions including triciribine and taxanes and methods of use thereof
09/04/2008WO2007084757A3 Diagnostic and therapeutic utility of tribbles-2 in human cancers
09/04/2008US20080214849 for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as cancer or leishmaniosis; (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
09/04/2008US20080214791 Human melanoma specific monoclonal antibody for use in diagnosis and treatment of cell proliferative disorders of the skin; tissue targeted therapy
09/04/2008US20080214680 Application of arsenic as a cancer prevention agent
09/04/2008US20080214674 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction
09/04/2008US20080214671 Administering dicarbonic acids as metastasis inhibitors and agents enhancing chemotherapeutic activity of anti-tumor agents; in combination with cisplatin at the minimum doses, completely inhibiting the metastasis process in experimental B-16 melanoma
09/04/2008US20080214659 Stage-Specific Reduction of LUTS in Prostate Disease
09/04/2008US20080214655 Paclitaxel or a paclitaxel analog and 2,5-Dimethoxythiobenzoic acid N-methylhydrazine; antitumor; nontoxic
09/04/2008US20080214623 N-(2,2-Dimethylpropyl)-6-{3-fluoro-5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl}-3-pyridinecarboxamide; inhibitors of p38 kinase
09/04/2008US20080214617 antitumor agents; anticancer agents; structurally related to the leptomycin family; Leptolstatin
09/04/2008US20080214615 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
09/04/2008US20080214612 for therapy of endometriosis and/or uterine leiomyoma/leiomyomata; 1-(2-{4-[2-(4-Methanesulfonyl-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine
09/04/2008US20080214606 Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
09/04/2008US20080214605 to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc.
09/04/2008US20080214604 Medicinal Composition
09/04/2008US20080214597 Tricyclic Lactam Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors
09/04/2008US20080214596 Determining the level of expression and/or phosphorylation state of S6;rapamycin; antitumor
09/04/2008US20080214594 Inhibitors Of Checkpoint Kinases
09/04/2008US20080214593 Tetracyclic amino and carboxamido compounds and methods of use thereof
09/04/2008US20080214586 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators
09/04/2008US20080214585 For abnormal cell proliferation, inflammatory diseases, asthma, and arthritis; (S)-N-{4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-4-methylene-L-glutamic acid disodium salt (CHL1007)
09/04/2008US20080214584 Method for treating cancer
09/04/2008US20080214582 treatment of tumors; 1-[4-(6-aminopurin-9-yl)-;phenyl]-3-[2-(pyrrolidin-3-yloxy)-5-trifluoromethylphenyl]-;urea; psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases
09/04/2008US20080214579 Thienopyrimidinediones and their use in the modulation of autoimmune disease
09/04/2008US20080214576 Topoisomerase Inhibitors and Prodrugs
09/04/2008US20080214573 Compounds Useful for Inhibiting Chk1
09/04/2008US20080214569 Use of phosphatases to treat tumors overexpressing N-CoR
09/04/2008US20080214567 Benzimidazole Thiophene Compounds
09/04/2008US20080214563 Benzimidazole Thiophene Compounds As Plk Modulators
09/04/2008US20080214558 2-[(2-(4-methylpyrazin-1-yl)-3-fluoro-5-pyridinyl)amino]-4-[(3-chloro-4-fluoro) or (3-cyanomethyl)phenylamino]pyrimidine; 2-[(4-(4-methylpyrazin-1-yl)-phenyl)amino]-4-[(3-chloro-4-fluoro) or (3-cyanomethyl)phenylamino]pyrimidine; colon, breast, stomach, urogenital, pancreatic cancers, leukemia lymphoma
09/04/2008US20080214548 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors
09/04/2008US20080214547 Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells
09/04/2008US20080214546 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
09/04/2008US20080214545 4-{3-tert-butyl-5-[({[4-(pyridin-4-yloxy)phenyl]amino}carbonyl)amino]-1H-pyrazol-1-yl}-N-(2-pyrrolidin-1-ylethyl)benzamide; antiproliferatives; angiogenesis inhibitors
09/04/2008US20080214544 N-(4-(6-(1-methyl-6-oxo-2-(phenylamino)-1,6-dihydropyrimidin-5-yl)pyridin-3-yloxy)pyridin-2-yl)pyrrolidine-1-carboxamide; anticarcinogenics, antiproliferatives, angiogenesis inhibitors; hepatocyte growth factor mediated diseases
09/04/2008US20080214543 Antiandrogen; prostate cancer; excellent oral pharmacokinetics
09/04/2008US20080214538 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics
09/04/2008US20080214521 N-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-Im]pyrrolo[3,4-j]][1,7]benzodiazonin-11-yl]-N-methylbenzamide; staurosporine derivative; FLT-3 kinase inhibitor, activator of permeabilization of mitochondrial outer membrane, as of BAK; anticarcinogenic
09/04/2008US20080214516 Methods and compositions for inhibiting tumor growth
09/04/2008US20080214509 Methods for enhancing the efficacy of vascular disrupting agents
09/04/2008US20080214499 Lowering lipids in a living body by use of a cyclic tetrasaccharide represented by formula of cyclo{>6)- alpha -D-glucopyranosyl-(1>3)- alpha -D-glucopyranosyl-(1>6)- alpha -D-glucopyranosyl-(1>3)- alpha -D-glucopyranosyl-(1>}, and/or glycosylated compound(s) thereof
09/04/2008US20080214491 Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products
09/04/2008US20080214488 TRIGGERED RNAi
09/04/2008US20080214483 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta)
09/04/2008US20080214470 Pin1-Modulating Compounds and Methods of Use Thereof
09/04/2008US20080214468 Administering a peptide, identified through a phage display library; osteogenesis, cell adhesion/angiogenesis, inhibiting cancer cell metastasis
09/04/2008US20080214466 Daily intravenous administration of VEGFR1R2-Fc Delta C1 or coadministration with a cytotoxic, chemotherapeutic or antigrowth agent, while gradually decreasing dosage of the antagonist; pancreatic cancer
09/04/2008US20080214465 Method of administering and using VEGF inhibitors for the treatment of human cancer
09/04/2008US20080214452 Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
09/04/2008US20080214446 Gene Introduction Efficiency Enhancer
09/04/2008US20080214445 Contains N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine
09/04/2008US20080214437 RNA interference; gene therapy; inhalers
09/04/2008US20080213890 Antibody-avidin fusion proteins as cytotoxic drugs
09/04/2008US20080213886 Albumin fusion proteins
09/04/2008US20080213884 Transgenic cell expressing vector comprising tissue specific regulatory sequences; tissue target gene expression
09/04/2008US20080213411 administering an effective amount of a soybean Kunitz trypsin inhibitor to a mammal; no side effects
09/04/2008US20080213399 Combination Therapies Using Hdac Inhibitors
09/04/2008US20080213388 Ecm to fill a space created after cancerous tumor excision
09/04/2008US20080213386 Vegetable, herbal-based dietary ingredients, extracts, which contain vitamins and nutrients that provide a novel nontoxic treatment for liver cancers, hepatitis, and liver cirrhosis
09/04/2008US20080213385 Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
09/04/2008US20080213382 Thermotherapy susceptors and methods of using same
09/04/2008US20080213374 Multi-kinase inhibitor, chemotherapeutics, pain relievers, anti-depressants, anti-inflammatories, ondansetron, nabilone, dronabinol, antibiotics, and antivirals; renal cancer; immune system; viral, bacterial infections; nausea; vomiting; pain; non-renal cancer; fatigue; skin irritation; bone marrow
09/04/2008US20080213351 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
09/04/2008US20080213314 Combined dna vaccine and biological modifiers for cancer therapy
09/04/2008US20080213310 Use of lytic toxins and toxin conjugates
09/04/2008US20080213306 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
09/04/2008US20080213303 Genetically modified cholera toxin (CT-CRM) comprising reduced toxicity and enhanced immunological response for use in preparation of vaccines against parasitic infection
09/04/2008US20080213302 Methods for treating cancer with MVA
09/04/2008US20080213289 Recombinant anti-cd30 antibodies and uses thereof
09/04/2008US20080213281 Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents
09/04/2008US20080213278 Using taxol and immunosuppressant administration as therapeutic treatment for immune-mediated and/or cell proliferative disorders
09/04/2008US20080213275 Use of mtki 1 for treating or preventing bone cancer
09/04/2008US20080213260 Administering an anti-CD23 antibody, an anti-CD20 antibody, and a chemotherapeutic agent; B cell chronic lymphocytic leukemia (B-CLL).
09/04/2008US20080213249 Conjugation; Fab fragments; for treatment of cancer metastasis
09/04/2008US20080213247 Mbms as Modifiers of Branching Morphogenesis and Methods of Use
09/04/2008US20080213240 RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK